March 30, 2017 / 1:12 PM / 4 months ago

BRIEF-Cellectar Biosciences initiates NCI-supported phase ii trial of CLR 131

1 Min Read

March 30 (Reuters) - Cellectar Biosciences Inc:

* After much anticipation, Cellectar Biosciences initiates NCI-supported phase ii trial of CLR 131 in multiple myeloma and other blood cancers

* Cellectar Biosciences-study will be conducted in up to 15 centers in U.S. for patients with variety of orphan-designated relapse or refractory hematologic cancers

* Cellectar Biosciences Inc - Cellectar will receive approximately $2 million in a non-dilutive grant to help fund trial from national cancer institute

* Cellectar Biosciences Inc - initial efficacy data from study expected as early as second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below